American Society of Nephrology (ASN)

Our News on Newswise
View All >

Prabir Roy-Chaudhury, MD, PhD, FASN, to Become Next President of the American Society of Nephrology

Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.
18-Oct-2024 3:15 PM EDT Add to Favorites

Newswise: 6712becab5b37_Cappelletto1017FINAL.docx.jpg

Preclinical Studies Test Novel Gene Therapy for Treating IgA Nephropathy

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and...
18-Oct-2024 3:55 PM EDT Add to Favorites

Trial Assesses Antibody Therapy for Chronic Active Antibody-Mediated Kidney Transplant Rejection

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized...
18-Oct-2024 3:50 PM EDT Add to Favorites

Researchers Test Imlifidase Enzyme Versus Plasma Exchange in Removing Donor-Specific Antibodies in Kidney Transplant Rejection Trial

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of...
18-Oct-2024 3:40 PM EDT Add to Favorites

High-Impact Clinical Trials Generate Promising Results for Improving Kidney Health: Part 2

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
18-Oct-2024 3:25 PM EDT Add to Favorites

Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk...
18-Oct-2024 4:10 PM EDT Add to Favorites

Newswise: 6712c22939c60_Untitleddrawing.jpg

Global, National, and Regional Trends in the Burden of Chronic Kidney Disease among Women

A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The...
18-Oct-2024 4:05 PM EDT Add to Favorites

How the Novel Antibody Felzartamab Impacts IgA Nephropathy

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce...
18-Oct-2024 3:50 PM EDT Add to Favorites

See All News

Our Experts on Newswise

American Society of Nephrology President and ASN Director of Policy and Government Affairs Comment on Trump Administration’s Overhaul of Kidney Care

10-Jul-2019 9:00 AM EDT

ASN Policy Expert and HIV Patient Advocate Available for Comment on Anticipated Passage of Hope ACT Today

12-Nov-2013 12:00 PM EST

See All Experts

Our YouTube Videos
View All >

About

About ASN
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has nearly 22,000 members representing 141 countries. For more information, visit www.asn-online.org and follow us on Facebook, X, LinkedIn, and Instagram.